Creative Biogene provides world-class production services for a variety of virus types using our QVirusTM platform. Based on our non-stop exploration and leading technologies, we have established multiple strategies and resources to assist in all areas of virus vector design and construction, as well as the generation of the virus in high titer for use in research.
Lentiviruses are a subset of retroviruses. They are some of the most common and useful viruses used throughout research. They have the ability to transduce both dividing and non-dividing cells without significant immune responses. Integrating stably into the host genome they enable long term transgene expression. Lentivirus has broad cell spectrum: infecting most cells, dividing & non-dividing. It is useful for both easy-to-transfect & hard-to-transfect cells.
Wild-type adenovirus, which includes human adenovirus type 5, is associated with various mild disorders, most notably mild to severe respiratory disease in humans. With a large packaging capacity (>8 kb), high titers, and high levels of transgene expression adenovirus is perfect for targeting a wide range of dividing and non-dividing cell types, with almost 100% efficiency. Another important fact is that adenoviruses do not integrate into the host genome.
AAV is a small, single-stranded DNA virus. AAV is thought to be non-pathogenic to humans, with replication possible in the presence of a helper virus, such as Adenovirus. They are not permanently integrated into the host genome. These features make AAV a useful tool for gene delivery into a wide variety of cell types and an attractive vector for gene therapy. AAV is commonly used for gene delivery in-vivo because of their mild immunogencity.
Retroviral vector is a powerful tool for delivering target genes into almost all types of dividing cells in vitro and in vivo. They are popular gene therapy vectors because they stably integrate the DNA copy of their genome into the host chromosome during their replication cycle. Advances in design of retroviral vectors have resulted in greater degree of biosafety, expanded host range, and increased stability of the virus particles. Retroviral vectors have been widely used in the ex vivo gene therapy protocols to correct the liver diseases in a wide variety of species.
The baculovirus expression vector systems (BEVS) use homologous recombination or site-specific transposition to produce recombinant virus encoding the protein of interest. Proteins produced in BEVS tend to be soluble and functional and carry post-translational modifications like phosphorylation and glycosylation. The system gives very high recombinant protein yields and it is often recommend it for proteins that are difficult to express in E. coli. It is also an efficient tool for preparing vaccines.
Oncolytic viruses selectively infect and kill cancer cells without harming normal tissue. To create this therapy, existing viruses are modified in the lab so that they can infect cancer cells, multiply, and destroy the cancer cells as well as the tumor mass. The viruses multiply in cancer cells but not in normal cells. In addition to being able to directly kill cancer cells, oncolytic viruses can trigger an anti-tumor immune response. Recently, one oncolytic virus has been approved for treatment of melanoma—the therapy is injected directly into the melanoma. Multiple clinical trials have shown promising results in several types of cancer.
With years of experience in research of oncolytic viruses as well as our QVirusTM platform, Creative Biogene expeditiously moves your oncolytic program forward for initial early-stage clinical evaluation. We provide a broad range of oncolytic virus engineering scope including herpes simplex virus, adenovirus, measles virus, vaccinia virus, vescilar stomatitis virus, and so on.